Time filter

Source Type

Borstel-Hohenraden, Germany

Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP.2013.1.2-2 | Award Amount: 13.07M | Year: 2014

Increase in antibiotic resistance is a global concern worldwide. The project NAREBs main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the therapy of multi-drug resistant (MDR) tuberculosis (TB) and MRSA infections in European MDR patients. NAREB will address the problem of drug bioavailability inside the infected macrophages, transport across the bacterial cell wall, and avoidance of escape mechanisms (expressed by the pathogen). The success of the utilization of nanoparticles in the improvement of drug targeting in other diseases opens the way for novel applications in nanotechnology-based treatments aimed at controlling MDR-TB and MRSA. Specific objectives to achieve the main goal are: (i) Screening of different combinations of antibiotic drugs (small chemical molecules and/or biomacromolecules - glycopeptides) with nanocarriers (lipid, polymeric, biopolymeric); (ii) Loading of Transcription Factor Decoys (TFDs) designed to block the expression of essential bacterial genes in compatible nanoparticle systems and their testing as novel antibacterials; (iii) In vitro and in vivo testing of the best therapeutic combinations in relevant experimental models and using innovative bioimaging; (iv) Improved formulations of multifunctional particles containing selected antibiotics and TFDs for increasing the bioavailability of active molecules in the site of infection (targeting strategy, adapted route of administration) (v) Assessing safety, regulatory and production (GLP/GMP) aspects in relation with the most promising nanoformulations; (vi) Clinical Development Plan for the preparatory work for the subsequent clinical testing of the selected nanoformulations. The project NAREB brings together 15 partners (including 4 SMEs and 1 industry) from 8 EU Member and Associated States with outstanding complementary expertise, ranging from material engineering to molecular biology, pharmacology and medicine.

Forschungszentrum Borstel and Albert Ludwigs University of Freiburg | Date: 2012-05-25

The present invention relates to a rhamno-polysaccharide antigen from

Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.1-1 | Award Amount: 7.78M | Year: 2012

Next generation sequencing (NGS) has fundamentally altered genomic research. New developments will bring NGS costs and performance down to an everybodys technology with extreme potential for ultra fast and accurate molecular typing and diagnostic as it provides the ultimate whole genome information. However, technical and bioinformatics constraints, restrict the application of NGS to few highly experienced laboratories. The goal of this project is the transition of NGS from a basic research tool to a highly efficient technology for pathogen typing and diagnostics on the EU level. This objective will be achieved by establishing a unique European consortium that brings together three SMEs leading in the fields of data to knowledge and NGS genome research with leading experts in clinical microbiology of three model pathogens of high European and worldwide importance (methicillin-resistant Staphylococcus aureus, Campylobacter spp., and M. tuberculosis complex. Particularly we will i) develop bio-informatics pipelines for quality-controlled and easy interpretation of NGS data, ii) optimize sample preparation steps and evaluate newest NGS (Ion Torrent) and Optical Mapping (OM) technologies, and iii) develop new, dedicated NGS-based pathogen diagnostic kits. Ultimate goal is to generate automatically plain language reports and to implement GIS and space-time cluster detections for automatic early-warning systems based on NGS-data. Application programming interfaces and a microbial typing ontology for a linked web will be developed. Product-like prototypic software development for automatic analysis of microbial NGS-data will be guided by two leading SMEs. The development of new and improved tools/technologies in this SME-targeted project will overcome existing obstacles of NGS and open the door for a wide application of NGS for European scientists and clinical microbiologist, thus fostering competitiveness of Europe in NGS research and medical applications.

Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2007-2.4.1-10 | Award Amount: 16.21M | Year: 2009

Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cells in the initiation, progression and metastasis of malignancy. The objective of the collaborative integrated project INFLA-CARE is to structure a European collective of scientific and technological excellence in the field of Inflammation & Cancer which will capitalise on the available expertise and develop effective anti-inflammatory strategies and novel agents for cancer prevention and treatment. The project will specifically seek to identify molecular and cellular targets for cancer therapy through the development and systematic study of state-of-the-art pre-clinical models of inflammation-driven cancer. By mobilising the outstanding research experience and technological capacities of the network participants, the program will accelerate the translation of knowledge obtained by basic research into new diagnostic and therapeutic strategies which will be used for the detection, prevention and improved management of several types of human cancer. INFLA-CARE will also ensure spreading of scientific excellence and dissemination of knowledge beyond the network, by encouraging innovation and transfer of knowledge and by raising public understanding of scientific and health issues. The impact of the program is therefore expected to be multi-dimensional, namely scientific, educational and innovation-related, enhancing European competitiveness and addressing major scientific issues and societal needs.

Forschungszentrum Borstel and Protectimmun GmbH | Date: 2013-10-21

A prophylactic antiallergenic composition includes at least one arabinogalactan or arabinogalactan protein. The arabinogalactan or arabinogalactan protein is isolated from a grass or corresponds in its structural arrangement to an arabinogalactan that can be isolated from a grass.

Discover hidden collaborations